
Why the clinic matters so much with peptides
With FDA-approved drugs, the product itself has been reviewed for safety, effectiveness and manufacturing quality. With compounded peptides, that review has not happened, so more of the burden falls on the prescriber and pharmacy. The clinic's judgment about whether a peptide is appropriate, and its choice of pharmacy, becomes a large part of your safety margin.
The rules are also moving. Several popular peptides, including BPC-157, TB-500, epitalon, MOTS-c, KPV and DSIP, were removed from FDA's Category 2 safety-risk list in 2026 after their nominations were withdrawn. In July 2026, an FDA advisory committee recommended adding five of them to the list of substances pharmacies may compound, while voting against DSIP. Those votes are advisory, and FDA had not finalized a rule as of this writing. A good clinic keeps up with this and tells you plainly where a specific peptide stands.
What good looks like
- A licensed clinician reviews your history, medications and goals before prescribing
- Baseline labs when they could reveal a more likely cause of your symptoms
- The dispensing pharmacy is named and is state-licensed
- Each peptide's regulatory status is described accurately, including that compounded peptides are not FDA-approved
- Evidence is described honestly, including when it comes mainly from animal studies
- A specific goal, a review date and a plan to stop if the goal is not met
- Clear instructions for storage, injection technique and side effects, without encouraging home mixing of raw powders
Red flags
- Products labeled for research use only or not for human consumption
- No clinician contact before a prescription is issued
- Refusal or inability to name the pharmacy
- Claims that peptides are natural and therefore safe
- Before-and-after testimonials or promised results
- Stacks of many peptides started at once, making side effects impossible to trace
- No questions about cancer history, pregnancy or competitive sport
Measure first
People often seek peptides for fatigue, slow recovery, poor sleep, low libido or stubborn weight. Each of those has common, testable causes, including iron deficiency, thyroid disease, low testosterone, poorly controlled blood sugar, sleep apnea and medication side effects. A clinic that orders relevant labs first may save you money and point you toward a better-proven treatment.
Evidence varies widely by peptide
Some peptides are FDA-approved drugs with large trials, such as semaglutide and tirzepatide for weight management and bremelanotide for a specific group of premenopausal women. Many others marketed for recovery, longevity or sleep rely mostly on laboratory and animal research. A good clinic will say which category a product falls into, rather than describing them all with the same confidence.
What follow-up should look like
Starting a peptide is the beginning, not the end, of the clinic's job. You should know when your first check-in is, what you will be asked about and how the clinic will judge progress against the goal you set. If labs were abnormal at the start, they should be repeated at a sensible interval. If you develop side effects, you should be able to reach a clinician promptly rather than waiting for a scheduled visit.
A good clinic is also comfortable recommending that you stop. If a peptide has not helped by the agreed review date, continuing simply adds cost and exposure without benefit.
Special situations
Anyone with a history of cancer should be especially cautious with peptides that influence growth pathways, such as growth hormone-releasing peptides. Peptides are not appropriate during pregnancy or breastfeeding. Many are banned in tested sports, so athletes should check anti-doping rules before starting.
Questions to ask
- Who is prescribing, and will I speak with them?
- Which pharmacy makes this product, and is it state-licensed?
- What is the FDA status of this specific peptide today?
- What human evidence supports using it for my goal?
- What labs do you want first, and why?
- How will we decide whether it is working, and when would we stop?
Applying this to HealifyMD
You can apply all of these criteria to HealifyMD. Our clinicians may prescribe certain compounded peptides when they judge them appropriate and when rules allow, filled by licensed U.S. pharmacies. They are not FDA-approved, and your clinician will explain the evidence limits. As examples, BPC-157 is listed from $250 per month and sermorelin ODT from $199 per month, with labs priced separately and prices confirmed during your eligibility review.
| Question | What you want to hear |
|---|---|
| Who prescribes? | A named, licensed clinician you can contact |
| Where is it made? | A named, state-licensed pharmacy |
| Is it FDA-approved? | A clear yes or no, with current regulatory status |
| What is the evidence? | Specific, including whether it is animal-only |
| What is the goal? | A measurable target and review date |
| When do we stop? | A defined exit plan |
Common questions
Are compounded peptides FDA-approved?
No. Compounded drugs are not FDA-approved and have not had FDA review for safety, effectiveness or quality.
Is it legal for a clinic to prescribe BPC-157?
Its status changed in 2026 and was still being finalized by FDA as of this writing, and some states set their own limits. Ask the clinic to explain the current status for your state.
Why should a clinic name its pharmacy?
Knowing the pharmacy lets you confirm it is state-licensed and gives you someone accountable for the product's quality.
Should I start several peptides at once?
Usually not. Starting one at a time makes it easier to tell what is helping and what is causing side effects.
Can a clinic guarantee results?
No responsible clinic can. Evidence for many peptides is limited, and individual responses vary.
Do I need labs before peptide therapy?
Often, yes. Labs can uncover common causes of symptoms that have better-supported treatments.
Sources
We cite government agencies, professional societies and peer-reviewed research. See our editorial policy.
- Certain bulk drug substances for use in compounding that may present significant safety risksU.S. Food and Drug Administration
- Bulk list bound? PCAC backs majority of peptides in two-day public meetingMcDermott Will & Schulte
- Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration
- Considering an online pharmacy?U.S. Food and Drug Administration